【摘要】 目的以阿米卡星为对照评价依替米星治疗下呼吸道感染的临床有效性及安全性。方法共入选病例140例,可评价疗效者120例,其中试验组(依替米星)与对照组(阿米卡星)分别为61例与59例。安全性评价入选病例131例,两组分别为65例与66例。给药方法试验组每次200mg,每日1次,对照组每次200mg,每日2次,两组疗程均为7~14d。结果试验组与对照组的临床有效率分别为91.80%与64.41%,细菌清除率分别为86.54%与66.00%,敏感菌百分率分别为94.23%与72.00%,听力下降发生率分别为1.54%与15.15%。以上结果经统计学处理两组差异有统计学意义。结论依替米星为治疗下呼吸道感染的安全、有效的抗菌药物。更多还原

【Abstract】 Objective To evaluate the efficacy and safety of etimicin compared with amikacin in the treatment of lower respiratory tract infections.Methods A total of 140 patients enrolled in the study.120 patients were evaluated for efficacy and 131 patients were evaluated for safety.Etimicin was administered once a day for 7～14 days at a daily dose of 200mg and amikacin was administered twice a day for 7～14 days at a daily dose of 400mg.Results The overall clinical efficacy rates of etimicin and amikacin were 91.80% and 64.41%,respectively.The bacteriological clearance rates of etimicin and amikacin were 86.54% and 66.00%,respectively.The bacterial susceptibility rates of etimicin and amikacin were 94.23% and 72.00%,respectively.The incidence of hearing loss for etimicin and amikacin were 1.54% and 15.15%,respectively.The study demonstrated that there were statistical differences between the two groups with respect to clinical efficacy,bacterial clearance and incidence of hearing loss.Conclusion Etimicin is a safe and effective antibiotic in treating lower respiratory tract infections with bacteria.更多还原